The mechanism of long-term low-dose asymmetric dimethylarginine inducing transforming growth factor-β expression in endothelial cells

International Journal of Molecular Medicine

Volumn 31, Issue 1, 2013, Pages 67-74

  Feng, Yiduo ^a   Zhang, Dongliang ^a   Zhang, Yu ^a   Zhang, Qidong ^a   Liu, Wenhu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Cytoskeleton; Endothelial cell; Nuclear factor B; Transforming growth factor

Indexed keywords

ACTIN DEPOLYMERIZING FACTOR; ACTIN STABILIZING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N(G),N(G) DIMETHYLARGININE; OXIDOREDUCTASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; STABILIZING AGENT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DNA PROTEIN COMPLEX; DRUG EXPOSURE; DRUG MECHANISM; DRUG TISSUE LEVEL; ELECTROPHORETIC MOBILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STRESS FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING;

ACTIN CYTOSKELETON; ACTINS; ARGININE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MESANGIAL CELLS; NADPH OXIDASE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84873187525     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1190     Document Type: Article

References (34)

1. Boger RH: Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the 'L-arginine paradox' and acts as a novel cardiovascular risk factor. J Nutr 134 (Suppl 10): S2842-S2853, 2004.
2. Cooke JP: Does ADMA cause endothelial dysfunction. Arterioscler Thromb Vasc Biol 20: 2032-2037, 2000.
3. Boger RH: Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 10 (Suppl 1): S19-S25, 2005.
4. Palm F, Onozato ML, Luo Z and Wilcox CS: Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293: H3227-H3245, 2007.
5. Teerlink T, Luo Z, Palm F and Wilcox CS: Cellular ADMA: regulation and action. Pharmacol Res 60: 448-460, 2009.
6. Scalera F, Borlak J, Beckmann B, et al: Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 24: 1816-1822, 2004.
7. Li JC, Chang L, Lu D, Jiang DJ and Tan DM: Effect of asymmetric dimethylarginine on the activation of hepatic stellate cells and its mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban 32: 427-432, 2007 (In Chinese).
8. Guo WK, Zhang DL, Wang XX, Zhang Y, Zhang QD and Liu WH: Actin cytoskeleton modulates ADMA-induced NF-kappaB nuclear translocation and ICAM-1 expression in endothelial cells. Med Sci Monit 17: BR242-BR247, 2011.
9. Fazal F, Minhajuddin M, Bijli KM, McGrath JL and Rahman A: Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translocation in endothelial cells. J Biol Chem 282: 3940-3950, 2007.
10. Wang LY, Zhang DL, Zheng JF, Zhang Y, Zhang QD and Li WH: Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides 32: 2436-2443, 2011.
11. Fliser D, Kronenberg F, Kielstein JT, et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005.
12. Zoccali C, Bode-Boger S, Mallamaci F, et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117, 2001.
13. Zoccali C: Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 70: 26-33, 2006.
14. Matsumoto Y, Ueda S, Yamagishi S, et al: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 18: 1525-1533, 2007.
15. Wagner L, Riggleman A, Erdely A, Couser W and Baylis C: Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 62: 532-536, 2002.
16. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F and Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455, 2005.
17. Mihout F, Shweke N, Bige N, et al: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol 223: 37-45, 2011.
18. Aggarwal BB: Nuclear factor-kappa B: the enemy within. Cancer Cell 6: 203-208, 2004.
19. Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
20. Karin M and Lin A: NF-kappa B at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
21. Wojciak-Stothard B, Torondel B, Tsang LY, et al: The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 120: 929-942, 2007.
22. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ and Satterwhite LL: Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc Res 71: 236-246, 2006.
23. Li JM and Shah AM: Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 277: 19952-19960, 2002.
24. Tamura M, Kai T, Tsunawaki S, Lambeth JD and Kameda K: Direct interaction of actin with p47(phox) of neutrophil NADPH oxidase. Biochem Biophys Res Commun 276: 1186-1190, 2000.
25. Wientjes FB, Reeves EP, Soskic V, Furthmayr H and Segal AW: The NADPH oxidase components p47(phox) and p40(phox) bind to moesin through their PX domain. Biochem Biophys Res Commun 289: 382-388, 2001.
26. Gerthoffer WT and Gunst SJ: Invited review: focal adhesion and small heat shock proteins in the regulation of actin remodeling and contractility in smooth muscle. J Appl Physiol 91: 963-972, 2001.
27. McMullen ME, Bryant PW, Glembotski CC, Vincent PA and Pumiglia KM: Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280: 20995-21003, 2005.
28. Lamalice L, Houle F, Jourdan G and Huot J: Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23: 434-445, 2004.
29. Garcia JG, Wang P, Schaphorst KL, et al: Critical involvement of p38 MAP kinase in pertussis toxin-induced cytoskeletal reorganization and lung permeability. FASEB J 16: 1064-1076, 2002.
30. Song C, Perides G, Wang D and Liu YF: beta-Amyloid peptide induces formation of actin stress fibers through p38 mitogen-activated protein kinase. J Neurochem 83: 828-836, 2002.
31. Okuda S, Languino LR, Ruoslahti E and Border WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86: 453-462, 1990.
32. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M and Fujishima M: TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 45: 525-536, 1994.
33. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC and Chatziantoniou C: Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132-1144, 2003.
34. Tomita H, Egashira K, Ohara Y, et al: Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32: 273-279, 1998.